SCHEMBL4278335

SCHEMBL4278335

C#CCC(C(=O)C(C(=O)OCC)C(=O)OCC)c1ccccn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.54
KMT2A Q03164 2/20 0.54
SMN1; SMN2 Q16637 2/20 0.54
GAA P10253 2/20 0.54
ALDH1A1 P00352 4/20 0.39
CYP1A2 P05177 2/20 0.39
LMNA P02545 2/20 0.39
KDM4E B2RXH2 5/20 0.38
CYP2C19 P33261 1/20 0.38
NPC1 O15118 3/20 0.36
MAPT P10636 2/20 0.36
NOS2 P35228 1/20 0.36
RAB9A P51151 1/20 0.36
CASP1 P29466 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CYP3A4 P08684 2/20 0.35
ABCB11 O95342 1/20 0.35
ESR1 P03372 1/20 0.35
ADRA2A P08913 1/20 0.35
CYP2C9 P11712 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1127868 0.90 MEN1 (0.59) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL13619603 0.81 MEN1 (0.52) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL1127316 0.81 MEN1 (0.52) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL4278338 0.81 MEN1 (0.40) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL13658265 0.79 SMN1; SMN2 (0.58) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL1127307 0.78 KMT2A (0.49) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL13619712 0.77 GAA (0.48) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL1127390 0.77 KMT2A (0.48) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL1127754 0.77 CYP1A2 (0.44) MEN1KMT2ASMN1; SMN2GAAALDH1A1
SCHEMBL13662211 0.76 CYP2C19 (0.39) MEN1KMT2ASMN1; SMN2GAAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2009134616-A2 NOVEL INHIBITORS OF HEPATITIS C VIRUS REPLICATION INTERMUNE, INC. (US) 2009-11-05 WO disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication INTERMUNE, INC. (US) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090257979-A1 Novel Inhibitors of Hepatitis C Virus Replication EIF2AK2, HAVCR2, HDGF MEN1 4723/4885KMT2A 2735/4885SMN1; SMN2 3563/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.